Crush It For Curtis Foundation Bladder Cancer Awareness Month Events!

Bladder Cancer Awareness is shaping up to be a busy one for Crush It For Curtis Foundation. We have several awareness tables that will be located throughout the Richmond, VA, and Durham, NC area. We are also supporting our bladder cancer partners BCAN and Fight Bladder Cancer UK to support additional awareness events to raise awareness to increase public consciousness about bladder cancer, advance bladder cancer research, and provide knowledge and support services for the bladder cancer community. CIFCF will also be hosting additional Facebook Live events throughout May stay tuned for those events! Download twibbon, Facebook and Twitter covers. May 1 – Virginia Urology – Stony Point Locat

Twibbon Contest Bladder Cancer Awareness Month Is Approaching!

Bladder Cancer Awareness Month Is Approaching! We need your help in creating this year 2019 Crush It For Curtis Foundations Bladder Cancer Awareness Twibbon! A Twibbon helps create buzz around awareness campaigns. The Twibbon should increase awareness around Bladder Cancer. The winner will receive a $25 Amazon gift card and be the featured 2019 Twibbon. Get creative! Twibbon Specs: Twibbon image should: Be in .PNG or .GIF format Be exactly 400 x 400 pixels Have a transparent background Send Submissions Due April 22th at 10am Attention 2019 Twibbon

FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma

On April 12, 2019, the Food and Drug Administration granted accelerated approval to erdafitinib (BALVERSA, Janssen Pharmaceutical Companies) for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Today, the FDA also approved the therascreen® FGFR RGQ RT-PCR Kit, developed by QIAGEN, for use as a companion diagnostic for this therapeutic indication. Erdafitinib a

Comparison of biopsy devices inupper tract urothelial carcinoma

Introduction A correct characterization of upper tract urothelial carcinoma (UTUC) lesions is fundamental to appropriately select patients suitable for endoscopic management. We analyzed the diagnostic yield of three different biopsy tools for the histology evaluation of the UTUC. Furthermore, the concordance between biopsy grading and final UTUC pathology results at specimen (i.e., after ureterectomy or radical nephroureterectomy—RNU) was evaluated. Read The Full Journal By Visiting SIU Academy



  • Facebook Social Icon
  • Twitter Social Icon
  • Instagram Social Icon

Crush It For Curtis Foundation is a 501 (c) (3) charitable organization |EIN 82-3212272

©2020 by Crush It For Curtis Foundation - Bobby The Bladder is ©2020 by Crush It For Curtis Foundation


Contact UsPhone: 804-629-6429